Michael Liss, MD, PhD, MAS, FACS Urology Oncology, Prostate Cancer
EA8171, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (CTMS# 18-0091)
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer, NRG-GU006 (CTMS# 18-0115)
This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer than radiation alone.